FROM THE EDITOR
Here is the fact that defines your CDMO risk: under FDA enforcement doctrine, the sponsor is legally responsible for product quality regardless of who makes the product. Your CDMO’s cGMP violation is your warning letter. Their data integrity failure is your import alert. Their inability to pass an inspection is your supply disruption — and potentially your consent decree.
FDA’s enforcement posture toward foreign contract manufacturers has tightened materially. For-cause inspections rose approximately 250% in 2025. Import alerts on foreign facilities multiplied. In early 2026, FDA deployed its Elsa AI tool to identify high-priority inspection targets from surveillance data — which means the list of facilities in the agency’s crosshair is now larger and more data-driven than it has ever been.
The legal function needs to own this exposure. Quality agreements are legal documents. Supplier qualification is a regulatory compliance obligation. And the concentration of pharmaceutical supply chains in India and China is now a national security framing that has the administration’s full attention — which means the enforcement resources are not going away.
— John LaRocca
Founding Editor | LaRocca Advisory Group
Your CDMO’s Warning Letter Is Your Problem
FDA has increased for-cause inspections 250%, deployed AI to pick its targets, and made clear it holds sponsors accountable for what their contract manufacturers do. The quality agreement in your files is not a defense. It’s evidence.
Format: Issue Brief | Covers: CDMO Oversight | Foreign Manufacturing Enforcement | Quality Agreements | Sponsor Liability | Supply Chain Risk
FDA’s enforcement against foreign contract manufacturers accelerated through 2025 and into 2026. For-cause inspections rose approximately 250% in 2025. More than 120 import alerts were issued on foreign facilities. The agency deployed an AI surveillance tool to prioritize its inspection queue. And in every one of those enforcement actions, the foundational legal principle was the same: the sponsor owns the violation, even when a CDMO committed it.
DOMAIN 1 THE ENFORCEMENT MATH
The numbers from 2025 forward represent a structural shift in FDA’s foreign inspection program, not a temporary spike.
CDER issued approximately 50% more warning letters in FY2025 than the prior year. About 35% of those letters cited cGMP violations at manufacturing sites. More than 120 new import alerts were issued on foreign facilities in 2025. For-cause inspections — the inspections triggered by specific compliance concerns rather than routine scheduling — rose approximately 250% over the same period.
The enforcement geography is concentrated. India and China together account for the majority of foreign drug manufacturing supplying the U.S. market: roughly 44% of active pharmaceutical ingredient Drug Master File holders are in India, 22% are in China, and only 9% are in the United States. Over half of branded drug products and nearly 70% of generics have at least one manufacturer outside the U.S.
FDA is now using its Elsa GenAI tool to identify high-priority inspection targets from surveillance data. The AI is picking the inspection queue. If your CDMO’s data patterns look like the facilities that have received warning letters, they are in the model.
The recurring violation themes are not new, but FDA’s tolerance for them has narrowed: unvalidated test methods, uninvestigated equipment excursions, data integrity lapses including incomplete or copied records, destruction of analytical records, backdated documents, and inadequate responses to Form 483 observations. Contract testing laboratories — the labs your CDMO may use for product release testing — have received their own warning letters, including actions against labs that FDA found had falsified or destroyed records.
FDA has also finalized guidance on Remote Regulatory Assessments and is reorganizing its inspectorate to support expansion. The agency’s planned shift to more unannounced inspections at foreign facilities is an explicit policy direction, not a threat. Plan for it.
DOMAIN 2 THE SPONSOR RESPONSIBILITY DOCTRINE
The foundational regulatory principle governing outsourced pharmaceutical manufacturing is straightforward and consistently enforced: the sponsor is legally responsible for the quality of its product regardless of who manufactures it. FDA treats contract manufacturers as extensions of the sponsor’s own facility. That is not a metaphor. It describes how FDA assigns enforcement consequences.
When FDA issues a warning letter to a CDMO, the sponsor’s products made at that facility are typically swept into the action. When FDA places a foreign facility on import alert, the sponsor’s ability to bring product made at that facility into the U.S. halts. The CDMO’s compliance failure becomes the sponsor’s supply interruption, the sponsor’s product recall exposure, and potentially the sponsor’s consent decree obligation.
Viatris learned this in December 2024, when FDA issued a warning letter and import alert covering 11 actively distributed products made at its Indore, India facility. The import alert barred those products from U.S. entry until the warning letter was lifted. Viatris implemented a remediation plan including corrective and preventive actions and independent third-party oversight, but the enforcement consequence — the market access interruption — preceded any of that remediation.
The quality agreement in your files does not limit your regulatory exposure. It documents who agreed to do what. FDA’s enforcement action will name the sponsor, not the CDMO’s quality director.
Six Asian manufacturing firms were placed on import alert in 2025 and 2026 for refusing to allow FDA inspections. Refusal to inspect is treated as equivalent to a significant cGMP failure for import alert purposes. If your CDMO refuses — or cannot logistically accommodate — an FDA inspection, your product is affected.
The legal function’s role in this framework is not to monitor GMP compliance directly. It is to ensure that the company’s quality agreements, supplier qualification processes, and supply chain contracts create an enforceable structure that the company can demonstrate to FDA and defend in an enforcement proceeding. The distinction matters. Legal doesn’t run quality; legal owns the contractual architecture that quality operates within.
DOMAIN 3 THE FOREIGN FACILITY PROBLEM
The administration has framed pharmaceutical supply chain concentration in China and India as a national security issue. Executive Order 14293 directed FDA and EPA to reduce regulatory barriers to domestic manufacturing, established the FDA PreCheck Program for streamlined domestic facility approvals, and called for higher fees and more frequent inspections of foreign plants.
This framing matters for CLOs because it means enforcement resources aimed at foreign manufacturing are not subject to the usual budget and priority competition. When supply chain vulnerability is national security, inspection activity at Indian and Chinese facilities becomes a policy imperative rather than a regulatory workload question. That is a different enforcement environment than pharma has operated in over the past decade.
The data integrity problem at foreign facilities is a specific concern that has driven disproportionate enforcement. Multiple warning letters in 2025 and 2026 cited contract testing labs outside the U.S. that had destroyed analytical records or backdated documents. When FDA finds those issues at a contract lab, it invalidates data from that lab retroactively — affecting product release testing for every sponsor that used that lab.
FDA has also signaled that it examines a sponsor’s other manufacturing and testing sites when it finds problems at one. The inspection of a single facility can trigger a review of the broader network. For sponsors using multiple foreign CDMOs or contract labs in concentrated geographies, that network effect is the compounding risk — a compliance failure at one site puts the entire foreign manufacturing footprint in scope.
The talc enforcement action in June 2026 illustrated this network sweep directly: CDER sent nine cGMP letters simultaneously to talc-product manufacturers in India, China, Japan, Turkey, Canada, the Dominican Republic, and the U.S. over asbestos contamination risk. The enforcement was coordinated across jurisdictions, not sequential. When FDA decides a product-class risk is systemic, the enforcement covers the supply chain.
DOMAIN 4 THE QUALITY AGREEMENT GAP
Quality agreements between sponsors and CDMOs are required under FDA guidance. They are also, in the current enforcement environment, significantly underengineered for the risks they’re supposed to manage.
The recurring failure modes identified in FDA’s 2025 and 2026 warning letters — data integrity lapses, uninvestigated out-of-specification results, inadequate change control, failure to report deviations — are all areas that a quality agreement should address explicitly. Most quality agreements in the market address them at a level of generality that does not produce actual compliance behavior. The agreement says the CDMO will report deviations. It doesn’t specify what constitutes a reportable deviation, what the timeline is, what the escalation path is when a deviation is unreported, or what the sponsor’s contractual remedy is when the CDMO fails to comply.
Contract testing laboratory oversight is the specific gap that FDA’s recent enforcement has exposed most sharply. Sponsors routinely rely on their CDMO’s contract lab relationships for product release testing. The quality agreement with the CDMO may say the CDMO is responsible for its subcontractors. But the sponsor has no direct contractual relationship with the testing lab, no direct audit rights, and no direct visibility into the lab’s data integrity practices.
When FDA finds that a contract lab destroyed records or backdated data, the invalidation of that lab’s testing data is retroactive. Products released based on that data face recall exposure regardless of what the quality agreement between the sponsor and the CDMO said. The contract allocation of responsibility does not bind FDA’s enforcement action.
The import alert contingency gap is equally significant. Most quality agreements address what happens when a product fails testing. Very few address what happens when the facility receives an import alert. The notice period, the product in transit, the in-process inventory, the back-up sourcing obligation — those are operational and legal questions that need contractual answers before the alert is issued, not after.
CLO WORKSTREAMS
■ Quality Agreement Audit. Pull every active quality agreement with a foreign CDMO or contract testing lab. Benchmark against FDA’s current enforcement themes: does each agreement specifically address deviation reporting timelines, data integrity obligations, change control notification, inspection access rights, and remediation escalation? Gaps in those areas are gaps in your regulatory defense.
■ Import Alert Contingency Protocol. For each foreign facility in your manufacturing network, establish a documented contingency protocol that addresses: in-transit inventory ownership and disposition, back-up sourcing timelines, regulatory notification obligations, and sponsor communication to affected customers. The time to build that protocol is before FDA issues the alert.
■ Foreign Supplier Risk Tiering. Tier your CDMOs and contract labs by geography, product criticality, and enforcement history. Facilities in India and China supplying critical products with no identified back-up source represent concentrated, compounding risk. That tier should receive priority audit attention and more robust quality agreement terms than your standard template provides.
■ Contract Testing Lab Direct Oversight. Map every contract testing lab your CDMOs use for product release, stability, or method validation. Confirm your quality agreements include either direct audit rights over those labs or CDMO-imposed oversight obligations with reporting to the sponsor. The retroactive data invalidation risk at contract labs is not adequately managed by a pass-through clause in the CDMO agreement.
■ Board Briefing on Supply Chain Concentration. The administration’s national security framing of pharmaceutical supply chain dependency is a board-level risk item. Brief the board on your company’s geographic concentration in foreign manufacturing, the enforcement trend data, your quality agreement coverage, and your import alert contingency posture. That briefing is also the basis for any capital allocation decision about domestic manufacturing investment.
For interested readers I created a CDMO Oversight Audit Toolkit. It can be found at https://laroccaadvisory.gumroad.com/l/unjhwk
John LaRocca is the Founding Editor of The GC Playbook and a fractional CLO at LaRocca Advisory Group, advising PE-backed specialty pharma and biotech companies on regulatory risk, supply chain governance, and transaction readiness.
laroccaj.substack.com | LaRocca Advisory Group
THE GC PLAYBOOK
Intelligence for pharma CLOs and GCs who can’t afford to be surprised.
laroccaj.substack.com


